Abstract

BackgroundCurrently there are many guidelines for the management of psoriatic arthritis which advocate the use of DMARDs (Disease Modifying Anti-Rheumatic Drugs) such as the EULAR (2011) and the BSR (2012)...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
A Joint Consensus of Rheumatologists and Dermatologists on Early Detection and Effective Management of Psoriatic Arthritis: India's Perspective.
Neeraj Jain ... Jatinder Singh
Indian journal of dermatology | VOL. 67
Neeraj Jain, et. al.Neeraj Jain ... Jatinder Singh
01 Feb 2022
AB0792 Current status and unmet needs in the management of psoriatic arthritis with conventional synthetic and biological disease modifying anti-rheumatic drugs: taiwanese nationwide physicians' perspectives
C-C Lai ... T-H Li
Annals of the Rheumatic Diseases | VOL. 76
C-C Lai, et. al.C-C Lai ... T-H Li
01 Jun 2017
The National Prevalence of Clinically Diagnosed Psoriatic Arthritis in Sweden 2017.
Sara Wedrén ... Johan K Wallman
The Journal of rheumatology | VOL. 50
Sara Wedrén, et. al.Sara Wedrén ... Johan K Wallman
01 Mar 2023
Real-life experience of using conventional disease-modifying anti-rheumatic drugs (DMARDs) in psoriatic arthritis (PsA). Retrospective analysis of the efficacy of methotrexate, sulfasalazine, and leflunomide in PsA in comparison to spondyloarthritides other than PsA and literature review of the use of conventional DMARDs in PsA.
Euthalia Roussou ... Aicha Bouraoui
European journal of rheumatology | VOL. 4
Euthalia Roussou, et. al.Euthalia Roussou ... Aicha Bouraoui
01 Mar 2017
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers